


JNJ-40255293

Cat. No.:	HY-122105
CAS No.:	1147271-25-7
Molecular Formula:	C ₂₃ H ₂₂ N ₄ O ₃
Molecular Weight:	402.45
Target:	Adenosine Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JNJ-40255293 is a high-affinity human A _{2A} receptor antagonist with a Ki of 7.5 nM. JNJ-40255293 can be used in the research of neurodegenerative diseases such as Parkinson's disease ^[1] .
In Vivo	JNJ-40255293 (0.1-10 mg/kg, p.o.) can reverse haloperidol (HY-14538)-induced catalepsy in male Balb/c mice. In male Wistar rats, JNJ-40255293 also dose-dependently reversed haloperidol (0.63 mg/kg, subcutaneous injection)-induced catalepsy, enhanced active arousal, and significantly reversed reserpine (HY-N0480) caused deficits in motor activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. John R Atack, et al. JNJ-40255293, a novel adenosine A_{2A}/A₁ antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA